← Leaderboards
Stephen Norman Thibodeau
Mayo Clinic Rochester
$86,704,246
Attributed
$175,707,045
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $54.2M · FY2005–23$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$175,707,045 · 10
By mechanism
U24$160,990,031 · 2
U01$10,090,104 · 2
R01$4,253,991 · 3
P30$372,919 · 1
P01$0 · 1
P50$0 · 1
Top collaborators
- Mine Cicek8 shared
- Noralane Morey Lindor6 shared
- Iftikhar J Kullo5 shared
- Paola A Ramos2 shared
- Travis Henry1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Mine Cicek$94,995,913
- Alanna Maguire$16,353,346
- Paola A Ramos$7,298,203
- Travis Henry$6,835,150
Others in their field
Top investigators on “Site”
- Lawrence Corey · Fred Hutchinson Cancer Center$727,416,881
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$630,131,001
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
SiteCostSamplingFamily GeneticsResourcesClinicBaseParticipantNeoplasm /Cancer GeneticsLaboratoriesGeneticMedicalBioinformaticsGenesMultidisciplinaryCancer RiskClinical ResearchPatient CareGene ExpressionFutureEnrollmentEnsureProtocols DocumentationCollection
Grant awards (47)
Precision Medicine Initiative Cohort Program Biobank$27,340,600
U24 · FY2023 · OD
Precision Medicine Initiative Cohort Program Biobank$1,805,861
U24 · FY2023 · OD · contact PI
Precision Medicine Initiative Cohort Program Biobank$1,389,160
U24 · FY2023 · OD
Precision Medicine Initiative Cohort Program Biobank$15,329,300
U24 · FY2022 · OD · contact PI
Precision Medicine Initiative Cohort Program Biobank$1,126,617
U24 · FY2022 · OD · contact PI
Precision Medicine Initiative Cohort Program Biobank$54,240,312
U24 · FY2020 · OD · contact PI
Precision Medicine Initiative Cohort Program Biobank$26,218,000
U24 · FY2017 · OD · contact PI
EHR-based Genomic Discovery and Implementation$840,645
U01 · FY2017 · HG
EHR-based Genomic Discovery and Implementation$98,698
U01 · FY2017 · HG
Precision Medicine Initiative Cohort Program Biobank$28,241,165
U24 · FY2016 · OD · contact PI
Prostate Cancer Susceptibility: The ICPCG Study$2,291,170
U01 · FY2016 · CA · contact PI
EHR-based Genomic Discovery and Implementation$849,369
U01 · FY2016 · HG
EHR-based Genomic Discovery and Implementation$233,600
U01 · FY2016 · HG
Prostate Cancer Susceptibility: The ICPCG Study$1,635,951
U01 · FY2015 · CA · contact PI
EHR-based Genomic Discovery and Implementation$859,901
U01 · FY2015 · HG
Functional Significance of Prostate Cancer risk-SNPs$359,898
R01 · FY2015 · CA · contact PI
Prostate Cancer Susceptibility: The ICPCG Study$1,604,043
U01 · FY2014 · CA · contact PI
Functional Significance of Prostate Cancer risk-SNPs$354,629
R01 · FY2014 · CA · contact PI
Prostate Cancer Susceptibility: The ICPCG Study$1,676,727
U01 · FY2013 · CA · contact PI
Functional Significance of Prostate Cancer risk-SNPs$353,610
R01 · FY2013 · CA · contact PI
Functional Significance of Prostate Cancer risk-SNPs$388,858
R01 · FY2012 · CA · contact PI
The Familial Colorectal Neoplasia Collaborative Group$1,277,837
U24 · FY2011 · CA · contact PI
Functional Significance of Prostate Cancer risk-SNPs$378,095
R01 · FY2011 · CA · contact PI
The Familial Colorectal Neoplasia Collaborative Group$1,304,966
U24 · FY2010 · CA
The Familial Colorectal Neoplasia Collaborative Group$1,321,718
U24 · FY2009 · CA
The Familial Colorectal Neoplasia Collaborative Group$222,055
U24 · FY2009 · CA
The Familial Colorectal Neoplasia Collaborative Group$18,800
U24 · FY2009 · CA
The Familial Colorectal Neoplasia Collaborative Group$1,153,640
U24 · FY2008 · CA
LOCALIZATION OF SUSCEPTIBILITY LOCI IN PROSTATE CANCER$328,324
R01 · FY2005 · CA
LOCALIZATION OF SUSCEPTIBILITY LOCI IN PROSTATE CANCER$319,346
R01 · FY2004 · CA
LOCALIZATION OF SUSCEPTIBILITY LOCI IN PROSTATE CANCER$310,046
R01 · FY2003 · CA
LOCALIZATION OF SUSCEPTIBILITY LOCI IN PROSTATE CANCER$343,659
R01 · FY2002 · CA
CLINICAL SIGNIFCANCE OF GENETIC MARKERS IN COLON CANCER$201,170
R01 · FY2002 · CA
Core--Gene discovery$72,259
P30 · FY2002 · CA
GENETIC LINKAGE ANALYSIS OF MAMMOGRAPHIC BREAST DENSITY$0
P01 · FY2002 · CA
GENETIC SUSCEPTIBILITY IN PROSTATE CANCER$0
P50 · FY2002 · CA
LOCALIZATION OF SUSCEPTIBILITY LOCI IN PROSTATE CANCER$333,648
R01 · FY2001 · CA
Core--Gene discovery$228,401
P30 · FY2001 · CA
CLINICAL SIGNIFCANCE OF GENETIC MARKERS IN COLON CANCER$195,602
R01 · FY2001 · CA
Core--Gene discovery$72,259
P30 · FY2001 · CA
GENETIC SUSCEPTIBILITY IN PROSTATE CANCER$0
P50 · FY2001 · CA
GENETIC LINKAGE ANALYSIS OF MAMMOGRAPHIC BREAST DENSITY$0
P01 · FY2001 · CA
LOCALIZATION OF SUSCEPTIBILITY LOCI IN PROSTATE CANCER$220,841
R01 · FY2000 · CA
CLINICAL SIGNIFCANCE OF GENETIC MARKERS IN COLON CANCER$166,265
R01 · FY2000 · CA
Core--Gene discovery$0
P30 · FY2000 · CA
Core--Gene discovery$0
P30 · FY2000 · CA
GENETIC LINKAGE ANALYSIS OF MAMMOGRAPHIC BREAST DENSITY$0
P01 · FY2000 · CA